What is Cardinal Health, Inc.'s earnings per share (EPS)?

Cardinal Health, Inc. (CAH) reported diluted earnings per share of $7.23 for fiscal year 2026. This represents a 12.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cardinal Health, Inc. (CAH) Financials

CAH

FY2026 annual

Revenue $254.2B +14.2% YoY

Net Income $1.7B +9.8% YoY

EPS (Diluted) $7.23 +12.1% YoY

Free Cash Flow $4.5B +144.6% YoY

Market Cap $55.5B as of Oct 14, 2026

Price / Sales 0.2x on $254.2B revenue, FY2026

Price / Earnings 32.4x on $1.7B net income, FY2026

Price / Book n/m negative shareholder equity, so no book multiple, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE June

Newest figures come from the 10-K for FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CAH SEC filings page.

Cardinal Health, Inc. (CAH) reported $254.2B in revenue for fiscal year 2026, up 14.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CAH FY2026 2026-10-04

Cardinal Health runs on enormous volume and thin margins; cash conversion improved, but short-term funding remains tight.

In FY2026, revenue reached $254.2B while operating margin remained just 1.0%, showing that added scale still flows through a cost-heavy model rather than creating broad fixed-cost absorption. Gross margin edged up to 3.8% from 3.7% in FY2025, indicating modest improvement in spread without a fundamental change in the business economics.

The balance sheet is increasingly dependent on current obligations: FY2026 inventory was $17.3B against $43.9B of current liabilities. That leaves a 0.9x current ratio and negative reported equity of -$2.9B, describing a leveraged financing structure rather than merely a weak profit year.

FY2026 net income of $1.7B became $5.2B of operating cash flow, so cash generation materially exceeded accounting profit. After $649M of capital spending, free cash flow was $4.5B, showing that the conversion was not dependent solely on non-cash earnings.

Financial Health Signals

Financial Health Score 44/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Cardinal Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Cardinal Health, Inc. has an operating margin of 1.0%, meaning the company retains $1 of operating profit per $100 of revenue. This results in a moderate score of 36/100, indicating healthy but not exceptional operating efficiency. This is unchanged from the prior year.

Growth

Cardinal Health, Inc.'s revenue grew 14.2% year-over-year to $254.2B, a solid pace of expansion. This earns a growth score of 53/100.

Leverage

Liquidity

Cardinal Health, Inc.'s current ratio of 0.88 is below the typical benchmark, resulting in a score of 14/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Cardinal Health, Inc. has a free cash flow margin of 1.8%, earning a moderate score of 30/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Altman Z-Score Safe

5.08

Cardinal Health, Inc. scores 5.08, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

8/9

Cardinal Health, Inc. passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.02x

For every $1 of reported earnings, Cardinal Health, Inc. generates $3.02 in operating cash flow ($5.2B OCF vs $1.7B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

7.51x

Cardinal Health, Inc. earns $7.51 in operating income for every $1 of interest expense ($2.6B vs $348.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$60.9B

QoQ-7.1%

Cardinal Health, Inc. generated $60.9B in revenue in Q4 2026. Against the prior quarter it is down 7.1%.

EBITDA

$1.2B

QoQ+30.1%

Cardinal Health, Inc.'s EBITDA was $1.2B in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is up 30.1%.

Net Income

$399.0M

QoQ-14.6%

Cardinal Health, Inc. reported $399.0M in net income in Q4 2026. Against the prior quarter it is down 14.6%.

EPS (Diluted)

$1.69

QoQ-14.2%

Cardinal Health, Inc. earned $1.69 per diluted share (EPS) in Q4 2026. Against the prior quarter it is down 14.2%.

Cash & Balance Sheet

Free Cash Flow

$1.7B

YoY+29.5%

QoQ+202.2%

5Y CAGR+56.8%

10Y CAGR+7.5%

Cardinal Health, Inc. generated $1.7B in free cash flow in Q4 2026, representing cash available after capex. This represents an increase of 29.5% from the same quarter a year earlier. Against the prior quarter it is up 202.2%.

Cash & Debt

$3.9B

YoY+1.6%

QoQ+41.8%

5Y CAGR+2.4%

10Y CAGR+4.2%

Cardinal Health, Inc. held $3.9B in cash against $8.2B in long-term debt as of Q4 2026.

Dividends Per Share

$0.51

QoQ0.0%

Cardinal Health, Inc. paid $0.51 per share in dividends in Q4 2026. It is unchanged from the prior quarter.

Shares Outstanding

234M

YoY-1.9%

QoQ-0.5%

5Y CAGR-4.2%

10Y CAGR-3.2%

Cardinal Health, Inc. had 234M shares outstanding in Q4 2026. This represents a decrease of 1.9% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Margins & Returns

Gross Margin

4.1%

QoQ+0.5pp

Cardinal Health, Inc.'s gross margin was 4.1% in Q4 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 0.5 percentage points.

Operating Margin

0.8%

QoQ-0.2pp

Cardinal Health, Inc.'s operating margin was 0.8% in Q4 2026, reflecting core business profitability. Against the prior quarter it is down 0.2 percentage points.

Net Margin

0.7%

QoQ-0.1pp

Cardinal Health, Inc.'s net profit margin was 0.7% in Q4 2026, showing the share of revenue converted to profit. Against the prior quarter it is down 0.1 percentage points.

Return on Equity

Not reported for Q4 2026.

Capital Allocation

Share Buybacks

$808.0M

QoQ+111.0%

5Y CAGR+32.2%

10Y CAGR+10.4%

Cardinal Health, Inc. spent $808.0M on share buybacks in Q4 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is up 111.0%.

Capital Expenditures

$146.0M

YoY-37.1%

QoQ+11.5%

5Y CAGR+7.9%

10Y CAGR+3.0%

Cardinal Health, Inc. invested $146.0M in capex in Q4 2026, funding long-term assets and infrastructure. This represents a decrease of 37.1% from the same quarter a year earlier. Against the prior quarter it is up 11.5%.

R&D Spending

Not reported for Q4 2026.

CAH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CAH quarterly income statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$254.2B+14.2%	$222.6B-1.9%	$226.8B+10.7%	$205.0B+13.0%	$181.3B+11.6%	$162.5B+6.2%	$152.9B+5.1%	$145.5B+6.4%	$136.8B+5.3%	$130.0B+6.9%	$121.5B+18.5%	$102.5B+12.6%	$91.1B-9.9%	$101.1B-6.0%	$107.6B
Cost of Revenue	$244.5B+14.0%	$214.4B-2.3%	$219.4B+10.8%	$198.1B+13.3%	$174.8B+12.3%	$155.7B+6.6%	$146.1B+5.3%	$138.7B+7.0%	$129.6B+5.0%	$123.4B+7.3%	$115.0B+18.8%	$96.8B+12.7%	$85.9B-10.7%	$96.2B-6.6%	$103.0B
Gross Profit	$9.8B+19.7%	$8.2B+10.2%	$7.4B+7.9%	$6.9B+6.0%	$6.5B-4.3%	$6.8B-1.3%	$6.9B+0.5%	$6.8B-4.8%	$7.2B+9.7%	$6.5B0.0%	$6.5B+14.5%	$5.7B+10.7%	$5.2B+4.9%	$4.9B+8.4%	$4.5B
SG&A Expenses	$6.1B+13.9%	$5.4B+7.6%	$5.0B+4.2%	$4.8B+6.4%	$4.5B-0.5%	$4.5B-0.9%	$4.6B+2.1%	$4.5B-2.5%	$4.6B+21.7%	$3.8B+3.5%	$3.6B+12.6%	$3.2B+7.0%	$3.0B+5.3%	$2.9B+7.4%	$2.7B
Operating Income	$2.6B+14.9%	$2.3B+83.0%	$1.2B+65.3%	$752.0M+223.9%	-$607.0M-228.6%	$472.0M+111.5%	-$4.1B-298.9%	$2.1B+1534.9%	$126.0M-94.1%	$2.1B-13.8%	$2.5B+13.8%	$2.2B+14.6%	$1.9B+89.3%	$996.0M-44.4%	$1.8B
EBITDA	$3.6B+16.4%	$3.1B+56.9%	$2.0B+35.2%	$1.4B+1598.8%	$85.0M-93.2%	$1.3B+139.4%	-$3.2B-204.1%	$3.1B+164.2%	$1.2B-59.2%	$2.8B-8.5%	$3.1B+18.7%	$2.6B+11.4%	$2.3B+68.3%	$1.4B-34.2%	$2.1B
Interest Expense	$348.0M+61.9%	$215.0M+321.6%	$51.0M-39.3%	$84.0M-42.9%	$147.0M-18.3%	$180.0M-24.4%	$238.0M-19.0%	$294.0M-10.6%	$329.0M+63.7%	$201.0M+12.9%	$178.0M+26.2%	$141.0M+6.0%	$133.0M+8.1%	$123.0M+29.5%	$95.0M
Income Tax	$469.0M-11.8%	$532.0M+52.9%	$348.0M+4.8%	$332.0M+117.0%	$153.0M+152.9%	-$289.0M-265.8%	-$79.0M-120.5%	$386.0M+179.3%	-$487.0M-177.3%	$630.0M-25.4%	$845.0M+11.9%	$755.0M+18.9%	$635.0M+14.8%	$553.0M-11.9%	$628.0M
Net Income	$1.7B+9.8%	$1.6B+83.2%	$852.0M+158.2%	$330.0M+135.2%	-$938.0M-253.5%	$611.0M+116.5%	-$3.7B-371.2%	$1.4B+432.4%	$256.0M-80.1%	$1.3B-9.7%	$1.4B+17.4%	$1.2B+4.2%	$1.2B+249.1%	$334.0M-68.8%	$1.1B
EPS (Basic)	$7.27+12.2%	$6.48+86.2%	$3.48+174.0%	$1.27+137.7%	-$3.37-261.2%	$2.09+116.6%	-$12.61-377.1%	$4.55+454.9%	$0.82-79.8%	$4.06-6.9%	$4.36+19.1%	$3.66+7.0%	$3.42+249.0%	$0.98-68.4%	$3.10
EPS (Diluted)	$7.23+12.1%	$6.45+87.0%	$3.45+173.8%	$1.26+137.4%	-$3.37-262.0%	$2.08+116.5%	-$12.61-378.4%	$4.53+459.3%	$0.81-79.9%	$4.03-6.7%	$4.32+19.3%	$3.62+7.1%	$3.38+248.5%	$0.97-68.3%	$3.06
Diluted Shares (Avg)	237M-2.1%	242M-2.0%	247M-5.7%	262M-6.1%	279M-5.1%	294M+0.3%	293M-2.7%	301M-4.4%	315M-1.6%	320M-3.0%	330M-1.5%	335M-2.9%	345M+0.3%	344M-1.4%	349M

Metric	Q4'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$60.9B	$65.6B+18.8%	$64.0B+22.4%	N/A	N/A	$55.3B-3.8%	$52.3B-4.3%	$59.9B+12.1%
Cost of Revenue	$58.4B	$63.2B+18.6%	$61.7B+22.5%	N/A	N/A	$53.3B-4.1%	$50.4B-4.8%	$58.0B+12.3%
Gross Profit	$2.5B	$2.4B+23.5%	$2.3B+21.9%	N/A	N/A	$1.9B+4.7%	$1.9B+9.1%	$1.9B+5.5%
SG&A Expenses	$1.5B	$1.5B+15.2%	$1.5B+14.4%	N/A	N/A	$1.3B+3.0%	$1.3B+7.7%	$1.3B+1.8%
Operating Income	$509.0M	$707.0M+28.8%	$668.0M+17.6%	N/A	N/A	$549.0M+8.7%	$568.0M+1875.0%	$401.0M+261.3%
EBITDA	$1.2B	$941.0M+27.0%	$901.0M+20.1%	N/A	N/A	$741.0M+9.0%	$750.0M+435.7%	$587.0M+104.5%
Interest Expense	$101.0M	$88.0M+151.4%	$80.0M+150.0%	N/A	$74.0M+164.3%	$35.0M+1066.7%	$32.0M+190.9%	$9.0M-10.0%
Income Tax	$12.0M	$159.0M+44.5%	$144.0M+16.1%	N/A	N/A	$110.0M-23.1%	$124.0M+475.8%	$158.0M+3.3%
Net Income	$399.0M	$467.0M+16.8%	$450.0M+8.2%	N/A	N/A	$400.0M+8.7%	$416.0M+3566.7%	$235.0M+519.6%
EPS (Basic)	$1.69	$1.98+20.0%	$1.89+10.5%	N/A	N/A	$1.65+10.0%	$1.71+3520.0%	N/A
EPS (Diluted)	$1.69	$1.97+19.4%	$1.88+10.6%	N/A	N/A	$1.65+10.0%	$1.70+3500.0%	N/A
Diluted Shares (Avg)	236M	237M-2.5%	239M-2.4%	N/A	N/A	243M-1.2%	245M-1.6%	N/A

Not reported in any period shown, so not listed: R&D Expenses.

CAH Balance Sheet

CAH quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$57.3B+7.9%	$53.1B+17.7%	$45.1B+4.1%	$43.3B-1.2%	$43.9B-1.3%	$44.5B+9.0%	$40.8B-0.5%	$41.0B+2.5%	$40.0B-0.4%	$40.1B+17.6%	$34.1B+13.2%	$30.1B+15.8%	$26.0B+0.8%	$25.8B+6.4%	$24.3B
Current Assets	$38.8B+6.5%	$36.4B+4.3%	$34.9B+3.4%	$33.7B+2.4%	$32.9B+6.1%	$31.0B+19.7%	$25.9B+0.7%	$25.7B+4.9%	$24.6B-13.4%	$28.3B+29.1%	$22.0B+0.9%	$21.8B+21.3%	$17.9B+1.0%	$17.8B+1.5%	$17.5B
Cash & Equivalents	$4.9B+25.3%	$3.9B-24.5%	$5.1B+25.9%	$4.1B-13.6%	$4.7B+38.5%	$3.4B+23.0%	$2.8B+9.5%	$2.5B+43.6%	$1.8B-74.4%	$6.9B+192.0%	$2.4B-49.0%	$4.6B+61.1%	$2.9B+50.7%	$1.9B-16.4%	$2.3B
Short-Term Investments	$0	$0-100.0%	$200.0M	$0	$0	$0	$0	$0	$0-100.0%	$65.0M-42.5%	$113.0M+24.2%	$91.0M-2.2%	$93.0M+29.2%	$72.0M0.0%	$72.0M
Inventory	$17.3B+2.8%	$16.8B+12.5%	$15.0B-7.2%	$16.1B+3.1%	$15.6B+7.1%	$14.6B+10.6%	$13.2B+2.9%	$12.8B+4.2%	$12.3B+8.9%	$11.3B+6.5%	$10.6B+15.2%	$9.2B+11.4%	$8.3B-1.3%	$8.4B+6.5%	$7.9B
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$87.0M-14.7%	$102.0M+1357.1%	$7.0M	$0	$0
Goodwill	$11.4B+18.1%	$9.7B+105.1%	$4.7B+2.4%	$4.6B-21.2%	$5.9B-26.7%	$8.0B-4.4%	$8.4B-0.3%	$8.4B+0.7%	$8.3B+15.2%	$7.2B+0.8%	$7.2B+41.4%	$5.1B+3.9%	$4.9B+6.0%	$4.6B+15.7%	$4.0B
Total Liabilities	$60.2B+7.7%	$55.9B+15.7%	$48.3B+4.4%	$46.3B+3.9%	$44.6B+4.5%	$42.7B+9.5%	$39.0B+12.5%	$34.6B+2.2%	$33.9B+1.8%	$33.3B+20.8%	$27.6B+15.4%	$23.9B+21.7%	$19.6B-1.1%	$19.8B+10.1%	$18.0B
Current Liabilities	$43.9B+12.9%	$38.9B+9.1%	$35.6B+5.6%	$33.7B+10.4%	$30.6B+10.6%	$27.6B+17.0%	$23.6B-2.0%	$24.1B+5.3%	$22.9B+7.9%	$21.2B+7.7%	$19.7B+14.3%	$17.2B+14.1%	$15.1B+3.6%	$14.6B+2.9%	$14.2B
Non-Current Liabilities	$16.3B-4.3%	$17.0B+34.0%	$12.7B+1.0%	$12.6B-10.5%	$14.0B-6.7%	$15.0B-2.1%	$15.4B+45.9%	$10.5B-4.3%	$11.0B-9.0%	$12.1B+53.6%	$7.9B+18.4%	$6.6B+47.1%	$4.5B-14.0%	$5.3B+36.8%	$3.8B
Long-Term Debt	$7.0B-12.2%	$8.0B+71.3%	$4.7B+19.2%	$3.9B-17.4%	$4.7B-11.7%	$5.4B-20.7%	$6.8B-10.7%	$7.6B-5.4%	$8.0B-11.6%	$9.1B+83.1%	$5.0B-5.0%	$5.2B+64.3%	$3.2B-14.0%	$3.7B+52.4%	$2.4B
Total Equity	-$2.9B-3.7%	-$2.8B+13.4%	-$3.2B-8.6%	-$3.0B-317.2%	-$709.0M-139.6%	$1.8B+0.1%	$1.8B-71.7%	$6.3B+4.4%	$6.1B-11.0%	$6.8B+3.9%	$6.6B+4.8%	$6.3B-2.3%	$6.4B+7.1%	$6.0B-4.3%	$6.2B
Retained Earnings	$2.0B+156.6%	$783.0M+373.8%	-$286.0M+55.5%	-$642.0M-129.3%	-$280.0M-123.2%	$1.2B+3.0%	$1.2B-78.5%	$5.4B+17.0%	$4.6B-6.5%	$5.0B-22.6%	$6.4B+16.3%	$5.5B+15.6%	$4.8B+18.2%	$4.0B-1.3%	$4.1B

Metric	Q4'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$56.7B+6.7%	$58.1B+23.6%	$55.2B+28.3%	$53.1B+17.7%	$49.9B+8.7%	$47.0B+0.9%	$43.1B-1.5%	$45.1B+4.1%
Current Assets	$38.1B+4.6%	$39.2B+9.7%	$38.5B+17.1%	$36.4B+4.3%	$34.6B-3.2%	$35.8B-5.1%	$32.9B-5.1%	$34.9B+3.4%
Cash & Equivalents	$3.9B+1.6%	$2.8B-27.1%	$4.6B+60.2%	$3.9B-24.5%	$3.3B-10.5%	$3.8B-17.0%	$2.9B-25.6%	$5.1B+25.9%
Short-Term Investments	N/A	$0	$0	$0-100.0%	$0	$0	$0	$200.0M
Inventory	$18.0B+7.0%	$20.1B+19.0%	$17.6B+12.4%	$16.8B+12.5%	$16.2B-6.5%	$16.9B-8.4%	$15.6B-8.1%	$15.0B-7.2%
Long-Term Investments	N/A	$0	$0	$0	$0	$0	$0	$0
Goodwill	$577.0M-94.0%	$11.6B+111.5%	$9.7B+105.5%	$9.7B+105.1%	$8.9B+86.0%	$5.5B+36.4%	$4.7B+17.4%	$4.7B+2.4%
Total Liabilities	$59.5B+6.5%	$61.0B+22.0%	$58.1B+25.4%	$55.9B+15.7%	$52.8B+7.5%	$50.0B-0.1%	$46.3B-1.8%	$48.3B+4.4%
Current Liabilities	$42.0B+7.9%	$43.3B+23.0%	$40.3B+16.1%	$38.9B+9.1%	$36.7B+1.0%	$35.2B-8.0%	$34.7B-1.1%	$35.6B+5.6%
Non-Current Liabilities	$17.5B+3.1%	$17.7B+19.5%	$17.8B+53.0%	$17.0B+34.0%	$16.2B+25.8%	$14.8B+25.9%	$11.7B-3.9%	$12.7B+1.0%
Long-Term Debt	$8.2B+3.4%	$8.3B+18.2%	$9.0B+112.6%	$8.0B+71.3%	$7.1B+52.9%	$7.1B+99.8%	$4.2B+8.6%	$4.7B+19.2%
Total Equity	-$2.8B-1.8%	-$2.9B+3.6%	-$2.9B+12.1%	-$2.8B+13.4%	-$2.9B+9.7%	-$3.0B+13.3%	-$3.3B+6.1%	-$3.2B-8.6%
Retained Earnings	$1.7B+121.2%	$1.5B+414.1%	$1.1B+7871.4%	$783.0M+373.8%	$664.0M+329.8%	$283.0M+166.6%	$14.0M+102.1%	-$286.0M+55.5%

Not reported in any period shown, so not listed: Accounts Receivable.

CAH Cash Flow Statement

CAH quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$5.2B+115.9%	$2.4B-36.3%	$3.8B+32.3%	$2.8B-10.4%	$3.2B+30.7%	$2.4B+23.9%	$2.0B-28.0%	$2.7B-1.7%	$2.8B+133.8%	$1.2B-60.1%	$3.0B+17.0%	$2.5B+0.6%	$2.5B+46.1%	$1.7B+46.9%	$1.2B
Depreciation & Amortization	$956.0M+21.0%	$790.0M+11.3%	$710.0M+2.6%	$692.0M0.0%	$692.0M-11.6%	$783.0M-14.2%	$913.0M-8.7%	$1.0B-3.1%	$1.0B+43.9%	$717.0M+11.9%	$641.0M+42.1%	$451.0M-1.7%	$459.0M+15.6%	$397.0M+22.2%	$325.0M
Stock-Based Compensation	$367.0M+50.4%	$244.0M+101.7%	$121.0M+26.0%	$96.0M+18.5%	$81.0M-9.0%	$89.0M-1.1%	$90.0M+9.8%	$82.0M-3.5%	$85.0M-11.5%	$96.0M-13.5%	$111.0M+0.9%	$110.0M+14.6%	$96.0M+3.2%	$93.0M+9.4%	$85.0M
Capital Expenditures	$649.0M+18.6%	$547.0M+7.0%	$511.0M+6.2%	$481.0M+24.3%	$387.0M-3.3%	$400.0M+6.7%	$375.0M+14.3%	$328.0M-14.6%	$384.0M-0.8%	$387.0M-16.8%	$465.0M+55.0%	$300.0M+20.5%	$249.0M+27.7%	$195.0M-25.0%	$260.0M
Free Cash Flow	$4.5B+144.6%	$1.9B-43.1%	$3.3B+37.6%	$2.4B-15.2%	$2.8B+37.4%	$2.0B+28.0%	$1.6B-33.8%	$2.4B+0.4%	$2.4B+199.1%	$797.0M-68.2%	$2.5B+11.9%	$2.2B-1.5%	$2.3B+48.5%	$1.5B+67.2%	$916.0M
Investing Cash Flow	-$2.6B+53.8%	-$5.6B-202.5%	-$1.8B-307.3%	-$454.0M-180.1%	$567.0M+250.0%	-$378.0M-176.7%	$493.0M+45.9%	$338.0M+106.0%	-$5.6B-1284.7%	-$405.0M+90.1%	-$4.1B-380.6%	-$849.0M+0.1%	-$850.0M+64.2%	-$2.4B-530.0%	-$377.0M
Financing Cash Flow	-$1.6B-182.6%	$1.9B+329.0%	-$847.0M+72.2%	-$3.1B-23.9%	-$2.5B-87.0%	-$1.3B+40.1%	-$2.2B+4.1%	-$2.3B-0.7%	-$2.3B-160.8%	$3.7B+428.9%	-$1.1B-1998.3%	$60.0M+108.5%	-$710.0M-358.2%	$275.0M+160.6%	-$454.0M
Dividends Paid	$491.0M-0.6%	$494.0M-1.0%	$499.0M-5.0%	$525.0M-6.1%	$559.0M-2.4%	$573.0M+0.7%	$569.0M-1.4%	$577.0M-0.7%	$581.0M+0.7%	$577.0M+12.7%	$512.0M+11.3%	$460.0M+10.8%	$415.0M+17.6%	$353.0M+17.7%	$300.0M
Share Buybacks	$1.4B+77.5%	$765.0M+2.0%	$750.0M-62.5%	$2.0B+100.0%	$1.0B+400.0%	$200.0M-42.9%	$350.0M-41.7%	$600.0M+9.1%	$550.0M-8.3%	$600.0M-7.8%	$651.0M-37.2%	$1.0B+53.9%	$673.0M+49.6%	$450.0M0.0%	$450.0M

Metric	Q4'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	$1.8B+19.4%	$686.0M+273.2%	$973.0M+159.1%	$1.5B-26.7%	$2.9B+10888.9%	-$396.0M-133.6%	-$1.6B-411.9%	$2.1B+141.3%
Depreciation & Amortization	$715.0M+242.1%	$234.0M+21.9%	$233.0M+28.0%	$209.0M+12.4%	$207.0M+16.9%	$192.0M+9.7%	$182.0M+5.8%	$186.0M+5.7%
Stock-Based Compensation	$309.0M	$31.0M+3.3%	$93.0M+210.0%	N/A	N/A	$30.0M+7.1%	$30.0M+3.4%	N/A
Capital Expenditures	$146.0M-37.1%	$131.0M+32.3%	$108.0M+20.0%	$232.0M+20.2%	$126.0M+12.5%	$99.0M-13.2%	$90.0M-2.2%	$193.0M-11.1%
Free Cash Flow	$1.7B+29.5%	$555.0M+212.1%	$865.0M+149.8%	$1.3B-31.4%	$2.8B+2105.0%	-$495.0M-146.5%	-$1.7B-498.4%	$1.9B+192.4%
Investing Cash Flow	-$181.0M+88.9%	-$2.0B-102.9%	-$142.0M-61.4%	-$1.6B-1082.5%	-$2.9B-56.9%	-$976.0M-829.5%	-$88.0M-39.7%	$166.0M+180.6%
Financing Cash Flow	-$483.0M-173.6%	-$519.0M-122.3%	-$110.0M+79.6%	$656.0M+176.4%	-$503.0M-148.8%	$2.3B+759.2%	-$540.0M+18.9%	-$859.0M-45.1%
Dividends Paid	$114.0M-5.0%	$128.0M0.0%	$129.0M+0.8%	$120.0M-1.6%	$124.0M+0.8%	$128.0M+4.1%	$128.0M-2.3%	$122.0M-3.2%
Share Buybacks	-$808.0M	$383.0M+2453.3%	$375.0M0.0%	$0	$375.0M	$15.0M-94.0%	$375.0M-25.0%	$0-100.0%

CAH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CAH quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	3.8%+0.2pp	3.7%+0.4pp	3.3%-0.1pp	3.4%-0.2pp	3.6%-0.6pp	4.2%-0.3pp	4.5%-0.2pp	4.7%-0.5pp	5.3%+0.2pp	5.0%-0.4pp	5.4%-0.2pp	5.6%-0.1pp	5.7%+0.8pp	4.9%+0.6pp	4.2%
Operating Margin	1.0%0.0pp	1.0%+0.5pp	0.5%+0.2pp	0.4%+0.7pp	-0.3%-0.6pp	0.3%+3.0pp	-2.7%-4.1pp	1.4%+1.3pp	0.1%-1.5pp	1.6%-0.4pp	2.0%-0.1pp	2.1%0.0pp	2.1%+1.1pp	1.0%-0.7pp	1.7%
Net Margin	0.7%0.0pp	0.7%+0.3pp	0.4%+0.2pp	0.2%+0.7pp	-0.5%-0.9pp	0.4%+2.8pp	-2.4%-3.4pp	0.9%+0.8pp	0.2%-0.8pp	1.0%-0.2pp	1.2%0.0pp	1.2%-0.1pp	1.3%+1.0pp	0.3%-0.7pp	1.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	34.1%+240.7pp	-206.6%-228.1pp	21.5%+17.3pp	4.2%-14.7pp	18.9%-2.8pp	21.8%+2.3pp	19.4%+1.2pp	18.2%+12.6pp	5.6%-11.5pp	17.1%
Return on Assets	3.0%+0.1pp	2.9%+1.0pp	1.9%+1.1pp	0.8%+2.9pp	-2.1%-3.5pp	1.4%+10.4pp	-9.1%-12.4pp	3.3%+2.7pp	0.6%-2.6pp	3.2%-1.0pp	4.2%+0.1pp	4.0%-0.4pp	4.5%+3.2pp	1.3%-3.1pp	4.4%
Current Ratio	0.88-0.1x	0.940.0x	0.980.0x	1.00-0.1x	1.080.0x	1.120.0x	1.100.0x	1.070.0x	1.07-0.3x	1.34+0.2x	1.11-0.1x	1.26+0.1x	1.190.0x	1.220.0x	1.24
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	3.00-0.8x	3.78+2.6x	1.20-0.1x	1.320.0x	1.33+0.6x	0.76-0.1x	0.83+0.3x	0.50-0.1x	0.62+0.2x	0.39
Asset Turnover	4.44+0.2x	4.19-0.8x	5.03+0.3x	4.73+0.6x	4.13+0.5x	3.65-0.1x	3.75+0.2x	3.55+0.1x	3.42+0.2x	3.24-0.3x	3.56+0.2x	3.40-0.1x	3.50-0.4x	3.92-0.5x	4.43
FCF Margin	1.8%+0.9pp	0.8%-0.6pp	1.4%+0.3pp	1.1%-0.4pp	1.5%+0.3pp	1.3%+0.2pp	1.0%-0.6pp	1.6%-0.1pp	1.7%+1.1pp	0.6%-1.4pp	2.1%-0.1pp	2.2%-0.3pp	2.5%+1.0pp	1.5%+0.7pp	0.9%

Metric	Q4'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	4.1%	3.6%+0.1pp	3.6%0.0pp	N/A	N/A	3.5%+0.3pp	3.6%+0.5pp	3.1%-0.2pp
Operating Margin	0.8%	1.1%+0.1pp	1.0%-0.1pp	N/A	N/A	1.0%+0.1pp	1.1%+1.1pp	0.7%+0.5pp
Net Margin	0.7%	0.7%0.0pp	0.7%-0.1pp	N/A	N/A	0.7%+0.1pp	0.8%+0.8pp	0.4%+0.5pp
Return on Assets	0.7%	0.8%-0.1pp	0.8%-0.2pp	N/A	N/A	0.9%+0.1pp	1.0%+1.0pp	0.5%+0.7pp
Current Ratio	0.910.0x	0.91-0.1x	0.960.0x	0.940.0x	0.940.0x	1.020.0x	0.950.0x	0.980.0x
Asset Turnover	1.07	1.130.0x	1.16-0.1x	N/A	N/A	1.18-0.1x	1.210.0x	1.33+0.1x
FCF Margin	2.8%	0.9%+1.8pp	1.4%+4.7pp	N/A	N/A	-0.9%-2.7pp	-3.3%-4.1pp	3.2%+2.0pp

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$2.9B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.88), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cardinal Health, Inc. CAH	FY2026	$254.2B	$1.7B	0.7%	$55.5B	44/100
Cencora, Inc. COR	FY2025	$321.3B	$1.6B	0.5%	$62.0B	50/100
McKesson Corporation MCK	FY2026	$403.4B	$4.8B	1.2%	$111.4B	55/100
Henry Schein Inc HSIC	FY2025	$13.2B	$419.0M	3.2%	$9.4B	46/100
ResMed Inc. RMD	FY2026	$5.7B	$1.5B	26.9%	$33.0B	87/100
Alcon Inc. ALC	FY2010	$7.2B	$2.2B	30.8%	$31.1B	—

Where Cardinal Health, Inc. Ranks

Frequently Asked Questions

What is Cardinal Health, Inc.'s annual revenue?

Cardinal Health, Inc. (CAH) reported $254.2B in total revenue for fiscal year 2026. This represents a 14.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cardinal Health, Inc.'s revenue growing?

Cardinal Health, Inc. (CAH) revenue grew by 14.2% year-over-year, from $222.6B to $254.2B in fiscal year 2026.

Is Cardinal Health, Inc. profitable?

Yes, Cardinal Health, Inc. (CAH) reported a net income of $1.7B in fiscal year 2026, with a net profit margin of 0.7%.

What is Cardinal Health, Inc.'s EBITDA?

Cardinal Health, Inc. (CAH) had EBITDA of $3.6B in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cardinal Health, Inc. have?

As of fiscal year 2026, Cardinal Health, Inc. (CAH) had $4.9B in cash and equivalents against $7.0B in long-term debt.

What is Cardinal Health, Inc.'s gross margin?

Cardinal Health, Inc. (CAH) had a gross margin of 3.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cardinal Health, Inc.'s operating margin?

Cardinal Health, Inc. (CAH) had an operating margin of 1.0% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Cardinal Health, Inc.'s net profit margin?

Cardinal Health, Inc. (CAH) had a net profit margin of 0.7% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Does Cardinal Health, Inc. pay dividends?

Yes, Cardinal Health, Inc. (CAH) paid $2.04 per share in dividends during fiscal year 2026.

What is Cardinal Health, Inc.'s free cash flow?

Cardinal Health, Inc. (CAH) generated $4.5B in free cash flow during fiscal year 2026. This represents a 144.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cardinal Health, Inc.'s operating cash flow?

Cardinal Health, Inc. (CAH) generated $5.2B in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Cardinal Health, Inc.'s total assets?

Cardinal Health, Inc. (CAH) had $57.3B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Cardinal Health, Inc.'s capital expenditures?

Cardinal Health, Inc. (CAH) invested $649.0M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

Does Cardinal Health, Inc. buy back shares?

Yes, Cardinal Health, Inc. (CAH) spent $1.4B on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Cardinal Health, Inc. have outstanding?

Cardinal Health, Inc. (CAH) had 233M shares outstanding as of fiscal year 2026.

What is Cardinal Health, Inc.'s current ratio?

Cardinal Health, Inc. (CAH) had a current ratio of 0.88 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

What is Cardinal Health, Inc.'s return on assets (ROA)?

Cardinal Health, Inc. (CAH) had a return on assets of 3.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Cardinal Health, Inc.'s P/E ratio?

Cardinal Health, Inc. (CAH) trades at 32.4x earnings, its market capitalization divided by net income of $1.7B net income, FY2026. The market capitalization is $55.5B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Cardinal Health, Inc.'s price-to-sales ratio?

Cardinal Health, Inc. (CAH) trades at 0.2x sales, its market capitalization divided by revenue of $254.2B revenue, FY2026. The market capitalization is $55.5B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is Cardinal Health, Inc.'s debt-to-equity ratio negative or not reported?

Cardinal Health, Inc. (CAH) has negative shareholder equity of -$2.9B as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Cardinal Health, Inc.'s Altman Z-Score?

Cardinal Health, Inc. (CAH) has an Altman Z-Score of 5.08, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Cardinal Health, Inc.'s Piotroski F-Score?

Cardinal Health, Inc. (CAH) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cardinal Health, Inc.'s earnings high quality?

Cardinal Health, Inc. (CAH) has an earnings quality ratio of 3.02x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cardinal Health, Inc. cover its interest payments?

Cardinal Health, Inc. (CAH) has an interest coverage ratio of 7.51x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Cardinal Health, Inc.?

Cardinal Health, Inc. (CAH) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.